With regard to Health Canada’s (HC) approval of the modRNA COVID-19 vaccines manufactured by Pfizer and Moderna and distributed throughout Canada, its mechanism of action and the elements of which they are comprised: (a) how many copies of the modRNA molecule are in a single dose, for both the Pfizer and Moderna products, (i) for adults, (ii) for children; (b) how many copies of the antigen are in a single adult dose of Novavax; (c) if there is a significant numerical difference between the answers for (a) and (b), does this affect the immunological response; (d) how many copies of dsDNA are found in a single 30 microliter adult dose of (i) Pfizer’s product, (ii) Moderna’s product; (e) was a request made to Pfizer-BioNTech and Moderna regarding the DNA size distribution in the vaccine and, if so, (i) what proportion of the total DNA quantity were under 200bp, (ii) what was the average, range and standard deviation; (f) what is the function of the modRNA; (g) what is the function of the lipid nanoparticles (LNPs); (h) what is the specific role(s) of N1-methyl-pseudouridine as used in the modRNA of the vaccines; (i) what safety data was available to HC at the time of approval and is currently available, regarding any and repeat exposure to the following in human cells (i.e., safety, efficacy, toxicity): (i) large amounts of N1-methyl-pseudouridine, (ii) dsRNA, (iii) cytosolic DNA, (iv) lipid nanoparticles; (j) with regard to the research underpinning (g), has a risk assessment been performed of the LNPs separately from that of the drug product for safety, toxicity; (k) does HC have any degradation data for the modRNA in the vaccines and, if so, what does the data show; (l) what is the duration of action of modRNA from the COVID-19 mRNA in the body and how was that measured; (m) in what cells and organs is spike protein most likely to be produced in the body; (n) in which cell types and tissues does the modRNA remain for the longest period of time and second longest period of time, and what are the time periods; (o) for what period of time does a person injected with modRNA produce spike protein; (p) is the production of spike protein dependent on cell type; (q) is there a known correlation between the amount of modRNA in the vaccine and the amount of spike protein produced by the cells; (r) has HC performed a risk assessment on the immunological, toxicological and carcinogenicity of the spike protein and, if so, what was the analysis, and, if not, why weren't these risk assessments considered necessary; (s) if production of spike protein antigen is prolonged for greater than three to five days, does prolonged exposure lead to ongoing production of antibodies; (t) if the answer to (s) is negative, will a study or investigation be undertaken to determine this; (u) if the answer to (s) is affirmative, and if antibodies are the indicator of immunity, why does efficacy wane with time when the antigen production is prolonged; (v) has the purity of the modRNA contained in the COVID-19 vaccines been determined; (w) if the answer to (v) is affirmative, what is the present accepted limit of fragmented and truncated modRNA; (x) if the answer to (v) is negative, why hasn’t the purity of the modRNA been established; (y) if production of spike protein expression is prolonged for more than three to five days, are there harmful sequelae to prolonged exposure; and (z) if the answer to (y) is affirmative, what are those harmful sequelae?
In the House of Commons on September 16th, 2024. See this statement in context.